Clinical trials: Molecular Imaging
Molecular Imaging
In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule
The investigators developed [68Ga]-labelling Anti-EGFR Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-ECD expression status.
- Trial name
- NCT02916329
- Testing
- 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Harbin Medical University
Prostate Cancer (Adenocarcinoma)
Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity
This is a single arm trial that is recruiting a total of 50 participants that have been diagnosed with prostate bed (where the prostate was taken out) or regional (surrounding lymph nodes) recurrence of a prostate cancer…
- Trial name
- MIDAS-SBRT (NCT07515651)
- Testing
- Image-guided Radiotherapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Migraine Headache, Migraine Without Aura
Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI
The investigators aim to investigate inflammation of cranial and meningeal arteries during pharmacologically induced migraine attacks, using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles and black blood imaging…
- Trial name
- NCT02549898
- Testing
- Feraheme, Cilostazol, USPIO-MRI
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Danish Headache Center
Ovarian Cancer
Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology
Patients with known ovarian cancer will be imaged up to four times with FDG-PET, C13 MRI and other novel MRI techniques during their treatment course including: before the start of any treatment (with optional repeat scanning)…
- Trial name
- MISSION-ovary (NCT03526809)
- Testing
- MRI scan and FDG-PET scan
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Renal Cell Carcinoma
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been…
- Trial name
- NCT03427476
- Testing
- CTT1057
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cancer Targeted Technology
Prostate Cancer, Prostate Neoplasm
Early and Accurate Detection of Prostate Cancer in General Practice
Prostate cancer (PC) is the most common malignancy (4500 new cases/year) and the second leading cause of cancer-associated mortality (1200 deaths/year) among men in Denmark.
- Conditions
- Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma
- Trial name
- NCT03431753
- Testing
- PSA, STHLM3 and mpMRI for PC detection
- Where
- Denmark
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Ischemic Heart Failure
FAPl Imaging Assessment of Revascularization Outcome in Ischemic Heart Failure
Ischemic heart failure (IHF) is the final stage of coronary heart disease. Coronary revascularization is an important treatment method for IHF, but it has high perioperative risks and not all patients can benefit from it.
- Trial name
- FARO (NCT07657650)
- Testing
- PCI (ercutaneous coronary intervention) and CABG (coronary artery bypass grafting, commonly known as heart bypass surgery)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Beijing Chao Yang Hospital
Gastric Cancer, Pancreatic Cancer
Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery
This study will evaluate the performance of the EnLightTM and LightPathTM Imaging Systems in detecting tumour lesions in patients with gastric, pancreas, bile duct or duodenal cancer.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Bile Duct Cancer, Duodenal Cancer
- Trial name
- CLIO (NCT02446379)
- Testing
- The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose, EnLightTM, LightPathTM Imaging System
- Where
- Hungary
- Sponsor
- Lightpoint Medical Limited
Healthy Volunteers, Alzheimer Disease
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
The imdazoline2 binding site (I2BS) is known to reside inside astrocytes. Changes in the numbers of I2BS in post mortem tissue has implicated them in a range of psychiatric conditions such as depression and addiction, along with…
- Conditions
- Healthy Volunteers, Alzheimer Disease, Molecular Imaging
- Trial name
- I2PETHV (NCT02323217)
- Testing
- [11C]BU99008, Idazoxan, Isocarboxazid
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HER2-positive Breast Cancer, Metastatic Cancer
PRE-ISPY Phase I/II Oncology Platform Program
PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced…
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic
- Trial name
- PRE-ISPY (NCT05868226)
- Testing
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab
- Where
- 10 sites in United States
- Volunteers
- 280 people
- Sponsor
- QuantumLeap Healthcare Collaborative
NSCLC
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma
Retrospective study in patients with therapy-naive non small cell lung carcinoma correlating presurgical F18-FDG-PET/CT imaging texture analysis data with postsurgical molecular pathology data and clinical patient outcome.
- Trial name
- PANU (NCT04276025)
- Testing
- Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
- Volunteers
- 2,000 people
- Sponsor
- Klinikum Bayreuth GmbH
Hepatocellular Carcinoma
PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer
This clinical trial evaluates whether 68Ga-PSMA PET/MRI or PET/CT can improve upon the diagnosis and management of liver cancer.
- Trial name
- NCT04310540
- Testing
- Biopsy, Computed Tomography, Gallium Ga 68 Gozetotide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer, Molecular Imaging
Molecular Evaluation in Metastatic Breast Cancer
Background: Despite that up 90% of patients with early-stage breast cancer receives adjuvant treatment, there are still about 300 patients diagnosed with primary metastatic breast cancer (MBC) and about 1,200 patients who develop…
- Trial name
- MESTAR (NCT03358589)
- Testing
- FDG-PET/CT
- Where
- Denmark
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Metastatic Breast Cancer (HR+/ HER2-)
Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast Cancer
This prospective observational study aims to evaluate the prognostic value of molecular imaging biomarkers derived from baseline [18F]FES and [18F]FDG PET/CT for progression-free survival in patients with estrogen receptor…
- Trial name
- NCT07867925
- Testing
- [18F] FES
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Breast Neoplasms
MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue
Primary: In women with heterogeneous or dense breast tissue (mammographic types 3 and 4), MBI (Molecular Breast Imaging) will detect more breast cancers and have greater sensitivity in detecting breast cancer than breast…
- Trial name
- NCT02013726
- Testing
- MBI Scan: The LumaGEM®, 3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Gamma Medica, Inc.
Prostate Cancer
Assessment of New Molecular Imaging Strategies for Prostate Cancer
In this study 30 men, with advanced metastatic Castration-Resistant Prostate Cancer (CRPC) planned to have hormonal treatment, will undergo conventional imaging and functional imaging prior to treatment and post treatment to…
- Trial name
- MISTER (NCT02813226)
- Testing
- Molecular Imaging
- Where
- 3 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Ovarian Cancer
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
The goal of this clinical research study is to find out if a combination treatment of perifosine and docetaxel will help shrink or slow the growth of cancer cells in recurrent ovarian cancer.
- Trial name
- NCT00431054
- Testing
- Perifosine, Docetaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Invasive Breast Cancer
Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer
This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features.
- Trial name
- NCT01597999
- Testing
- MRI
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Mahidol University
Age Related Macular Degeneration
Molecular Imaging Exploration of Ocular Angiogenic Activity and Evaluation of Its Interest in the Therapeutic Follow-up of Patients With AMD (Age-related Macular Degeneration)
The main objective of this pilot study is to evaluate the ability of 68Ga-NODAGA-RGD PET imaging to demonstrate, in patients with unilateral AMD, a molecular therapeutic response to intraocular antiangiogenic injections at the…
- Trial name
- DMLA-RGD (NCT04005443)
- Testing
- radiopharmaceutical
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Stage III Non-small Cell Lung Cancer, Unresectable Stage III NSCLC
In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy
PulmoPrint is a clinical study at the University Medical Center Groningen (UMCG) that investigates why some patients with unresectable stage III lung cancer don't respond to immunotherapy after chemoradiotherapy.
- Trial name
- PulmoPrint (NCT07653438)
- Testing
- Fluorescence molecular imaging during bronchoscopy with durvalumab-680LT
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen